Focused On-demand Library for Small ribosomal subunit protein uS9m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P82933

UPID:

RT09_HUMAN

Alternative names:

28S ribosomal protein S9, mitochondrial

Alternative UPACC:

P82933; Q6PG40

Background:

The Small ribosomal subunit protein uS9m, also known as 28S ribosomal protein S9, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the machinery responsible for protein synthesis within mitochondria, reflecting its importance in cellular energy metabolism and production. The protein's involvement in the mitochondrial ribosome highlights its contribution to the translation of mitochondrially encoded proteins, essential for mitochondrial function.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS9m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a potential target for interventions aimed at mitochondrial diseases or disorders associated with mitochondrial dysfunction.